E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059193 |
E.1.2 | Term | Acute hepatitis B |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- Is time to bilirubin < 2mg/dl shortened by the treatment with lamivudine?
|
|
E.2.2 | Secondary objectives of the trial |
- Is the time to clear HBV-DNA/HBeAg/HBsAg and/or development of anti-HBe/anti- HBs shortened by the treatment with lamivudine? - Is the rate of HBsAg positive patients at 6 resp. 12 month lowered by the treatment with lamivudine? - If initiallly abnormal: Is the time to normalization of prothrombin time (Quick ≥70%) and liver enzymes ALAT, ASAT shortened by the treatment with lamivudine? - Is the rate of patients progressing to fulminant hepatitis lowered by the treatment with lamivudine? - Is the rate of Adverse and Serious Adverse Events similar in both treatment arms? - For patients with ongoing employment relationship: Is the time to end of absence from work shortened by the treatment with lamivudine?
In addition, the aspects of quality of life/physical capacity resp. health economics will be adressed within two independent sub-studies. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
1.) Analysis of single nucleotide polymorphisms, 03.04.2006, final version: Objectives: Is there a difference in frequency for certain SNP in patients with acute vs. chronic hepatitis B?
2.) Immune genetics in HBV, 03.04.2006, final version: Objectives: Are SNP on Chromosome 6 and 21 associated with severe acute hepatitis B?
3.) Immunology in acute HBV infection, 03.04.2006, final version: Objectives: Is viral clearance associated with an immune response against HBsAg or HBcAg?
4.) HBV-Genetics in acute HBV-Infection, 03.04.2006, final version: Objectives: To assess HBV variants (genotypes, precore ane basal core promotor, polymerase and preS/S-gene) as predictors for antiviral treatment efficacy in acute hepatitis B.
5.) ASSESSMENT OF QUALITY OF LIFE Objectives: Is the quality of life impaired by acute hepatitis B, and does this impairment persist after viral clearance?
6.) HEALTH ECONOMICS Objectives: Is treatment intervention with lamivudine cost effective? Economic evaluation of lamivudine in the treatment of acute hepatitis B.
|
|
E.3 | Principal inclusion criteria |
- Acute hepatitis - HBsAg positive - Compensated liver function (Quick > 50%) - Bilirubin > 5mg/dl (i.e. >85µmol/l) - ALAT > 10 times upper normal range - Age >= 18 years - Time since diagnosis < 8 days - Written informed consent of the patient |
|
E.4 | Principal exclusion criteria |
- Known or obvious pre-existing liver disease (by e.g. spider naevis, ascites) - Ongoing interferon therapy or stop of interferon less than 3 months ago - Ongoing drug abuse - HIV positive - Anti-HCV or HCV-RNA positive - Anti-HDV positive - Renal insufficiency (creatinine >1.5mg/dl or 135µmol/l) - Pregnant or nursing women - Women with child bearing potential (< 2 years after last menstruation) without effective contraception - Use of oral contraception - Patient with transplanted organs - Any disease requiring immunosuppressive therapy, incl. cancer chemotherapy - Any acute infectious disease requires administration of sulphonamide/ trimethoprim - Evidence of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or patient at high risk from treatment complications - Known hypersensitivity to any of the study drugs or its ingredients - Current or recent (within 30 days prior to start of trial treatment) treatment with another investigational drug or participation in another investigational trial - Expected low compliance (e.g. by travel distance to trial site) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time until Bilirubin < 2 mg/dl
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 75 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |